Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page
- ChecktodayChange DetectedThe page has updated its date information, adding new dates for events in 2025 and 2026 while removing some earlier dates in 2025.SummaryDifference0.6%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a phase II clinical trial for treating relapsed follicular lymphoma and diffuse large B-cell lymphoma, while adding new identifiers and collaborators related to the study.SummaryDifference52%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and has changed the date references from March 25, 2025, to April 1 and April 2, 2025.SummaryDifference0.6%
- Check37 days agoChange DetectedThe page has been updated to reflect the latest information on B-cell Lymphoma, with the last update date changed to March 25, 2025, and the revision number updated to v2.14.3. The previous mention of Lymphosarcoma has been removed.SummaryDifference0.5%
- Check44 days agoChange DetectedDifference0.2%
Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.